GlassScriptPhysician profile
Douglas Piernick
NPI 1487053575
$5,103.19
in general payments reported to CMS, 2019-2025
24 companies · $1,895 in 2025
The $1,895 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.28 · 2020: $52.39 · 2021: $176 · 2022: $449 · 2023: $544 · 2024: $1,956 · 2025: $1,895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,103 · Education: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,103.09 |
| Education | $291.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,252.52 | 2019-2025 | |
| Genzyme Corporation | $781.53 | 2021-2025 | |
| Janssen Biotech, INC. | $725.15 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $350.03 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $311.30 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $287.63 | 2023-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $192.98 | 2023-2025 | Ilumya |
| Pfizer INC. | $140.60 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $127.80 | 2022-2025 | Dupixent |
| Galderma Laboratories, L.P. | $127.51 | 2024-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.14 | 2022-2025 | Spevigo |
| Incyte Corporation | $110.25 | 2022-2025 | Opzelura |
| Organon LLC | $89.37 | 2025 | Vtama |
| Genentech USA, INC. | $80.60 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $80.15 | 2023-2025 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $72.82 | 2025 | Bimzelx |
| Dermavant Sciences, INC. | $63.81 | 2024 | Vtama |
| Almirall LLC | $57.67 | 2022-2024 | Seysara |
| Convatec INC. | $48.06 | 2024 | |
| Boston Scientific Corporation | $25.00 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.32 | 2021 | |
| Lnhc, INC | $15.56 | 2025 | Zelsuvmi |
| Amgen INC. | $13.22 | 2024 | Otezla |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Piernick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.